Introduction
Tumor initiating cells (TIC), a small population of cells within a tumor capable of turning on selfrenewal properties, are thought to be responsible for tumor recurrence, metastasis and chemoresistance in a tumor. While there has been extensive research on this population of cells in pancreatic cancer and several studies have associated this population with poor prognosis, the molecular mechanisms of how these self-renewal genes are activated has remained an enigma.
Self-renewal in any cell is regulated by a concerted action of the "Yamanaka factors" SOX2, OCT4, Myc and KLF4 (1) . These transcription factors are robustly regulated by a number of interacting signaling pathways as well as cellular metabolism (2) .Alteration in tumor metabolism and/or bioenergetics pathways in cancer have recently emerged as a new cancer hallmark (3) .
Cancer cells undergo drastic metabolic reprogramming that not only results in the classic Warburg
Effect producing a large amount of lactate, but also in channeling a large amount of metabolites through biosynthetic pathways that support rapid growth and proliferation (4) . Among these, the hexosamine biosynthesis pathway or HBP has emerged as a critical node that is instrumental in the regulation of a number of pro-oncogenic pathways (5) (6) (7) . This pathway, often considered as a "nutrient-sensing" pathway, is a shunt pathway of glycolysis, uses fructose-6-and glutamine to produce glucosamine-6-phosphate. About 2-3% of the total cellular glucose is channelized via HBP to culminate in synthesis of the nucleic acid sugar UDP-GlcNAc. UDP-GlcNAc is one of the major substrates for both N-linked glycosylation as well as O-GlcNAcylation of proteins. Since the HBP is dependent on the availability of glucose, slight increases in glucose uptake results in significantly more O-GlcNAcylated modifications of many proteins (8) (9) (10) .
Protein O-GlcNAcylation is mediated via the activity of the enzyme O-GlcNAc Transferase (OGT).
A large number of proteins, particularly transcription factors are modified by OGT. This modification affects subcellular localization, protein-protein interaction or DNA binding ability of these proteins (11) . Research from our group has shown that modification of Sp1 by OGT facilitates its nuclear translocation and thus regulates its transcriptional activity (5) . A number of studies have been focused on how O-GlcNAc modification of pro-survival transcription factors may regulate tumor progression (11) . Even though the O-GlcNAc modifications of transcription factors are well known, the regulation of self-renewal genes in cancer by O-GlcNAc modification is a relatively understudied area. Recent reports have shown that SOX2 and OCT4, the key transcription factors that regulate self-renewal in embryonic stem cells and induced pluripotent stem cells are modified by O-GlcNAc (12) . In a recent study by Myers et al, O-GlcNAc modification of SOX2 regulates its interaction with PARP, which in turn led to differentiation (12) . However, there is no report on how O-GlcNAc modification of SOX2 regulates the self-renewal properties in a tumor cell.
Hexosamine biosynthesis pathway, and particularly OGT expression is upregulated in pancreatic cancer (6, 13, 14) . Studies from our laboratory have shown that O-GlcNAc modification of Sp1 regulates its nuclear translocation and thus its activity (5) . We have also shown that O-GlcNAc modification of β-catenin in pancreatic cancer regulates the Wnt signaling pathway (15) . In the current study, we have evaluated the role of O-GlcNAc modification on SOX2, the key transcription factor regulating self-renewal in cancer cells. Our results show that SOX2 is modified by O-GlcNAc transferase. O-GlcNAcylation of SOX2 stabilizes the protein in the nucleus and thus regulates its transcriptional activity. Further, mutating the Sox2 glycosylation site (S246A) prevents its O-GlcNAc modification and enhances its degradation. Inhibition of OGT in pancreatic cancer cells leads to a decrease in tumor initiation both in vivo and clonogenicity in vitro. This is the first report describing the O-GlcNAc modification of SOX2 in cancer cells and its role in regulation of self-renewal.
MATERIALS AND METHODS

Cell Culture
S2-VP10, and L3.6pL (a generous gift from Dr. Masato Yamamoto, University of Minnesota) cells were grown in RPMI 1640 -Gibco) and DMEM without NEAA containing 10% Fetal Bovine Serum (FBS) and 1% Penicillin/Streptomycin respectively. SU86.86 (ATCC) cell line was also cultured in RPMI 1640 ( Gibco) with 10% FBS and 1% Penicillin/Streptomycin. Human pancreatic stellate cells (ATCC, Manassas, VA, USA) were cultured in stellate cell medium (ScienCell, 5301) with stellate cell growth supplements provided by the manufacturer (SteCGS, Cat. No. 5352, P/S, Cat.
No. 0503) ScienCell, Carlsbad, CA, USA. All cell lines were routinely tested for mycoplasma contamination and STR profiles (ATCC).
Transcriptome deep sequencing and analysis
Aliquots of RNA were derived from the qRT-PCR samples. 3 independent passages of OGTi and the respective sham shcells were analyzed. The RNA was quality tested using a Bioanalyzer 2100 (Agilent Technologies, CA, USA). cDNA was created by reverse transcription of oligo-dT purified polyadenylated RNA and fragmented, blunt-ended, and then ligated to barcoded adaptors. Then, the library was size selected, and the selection process was validated and quantified by capillary electrophoresis and qPCR, respectively. Samples were load on the HiSeq 2500 (Illumina Inc., CA, USA) to generate around 34 million paired-end 50bp reads for each sample.
Raw sequence data was processed through PartekFlow RNAseq pipeline (Partek Inc., St. Louis, MO) as follows-A pre-alignment QA/QC was performed and bases with Q>30 were retained for analysis. Bowtie2 was used to filter out non-human DNA, mtDNA and rDNA from the samples and STAR 2.5.3 aligner was used to map the high-quality reads to Hg19 human genome assembly. Aligned reads were quantified for differential abundance among samples using (a) Partek E/M annotation model and (b) Cufflinks algorithm using the Hg19-Ensemble transcripts release 75.
Site Directed Mutagenesis
pDONR223_SOX2_WT obtained from Addgene (plasmid # 82233). SOX2 was modified at S246 to Alanine using QC Lightning Multi SITE DIRECTED MUTAGENESIS kit from Agilent according to manufacturer's instruction. Clones were confirmed by sequencing (16 
Generation of OGT-Knockout Cell line
Human OGT gene knockout kit was obtained from Origene, Rockville, MD, USA (KN206822). S2-VP10 cells were plated at a density of 80,000 in a 6 -well plate. One day after plating the cells were transfected with gRNA1 and gRNA2 along with donor vector. The cells were then cultured according to the manufacturer's protocols. After 8 passages puromycin pressure at a concentration of 0.5µg/ml was applied. The colonies were allowed to grow and the cells were then single-cell sorted by FACS in a 96-well plate. The select clones were allowed to grow and then characterized by mRNA expression and western blot.
Proximal Ligation Assay
S2VP10 and L3.6pL cells were plated at a density of 50,000 cell per well in a chamber slide. Cells were treated with OSMI for 24 hours. After 24 hour's media was removed, the cells were washed 3 times with PBS and fixed with 2% paraformaldehyde. After fixing the cells, they were stained according to the manufacturer's protocol (Duo link, DU 092101, SIGMA) and the images were acquired at 20X magnification.
In vivo Studies
Female athymic nude mice between the ages of 4-6 weeks were used for in vivo experiments and were purchased from the Jackson laboratory, Bar Harbour, ME, USA. For subcutaneous experiments 500,000 cells were implanted in the right flank of the mice. Corning® Matrigel® Growth Factor Reduced (GFR) Basement Membrane Matrix, purchased from Corning, inc, Corning NY, USA and 1X PBS at a ratio of 1:1 were used as a suspension medium for the cells.
Tumors were allowed to reach a size of 100mm 3 and then treatment was started. OSMI (SML1621 SIGMA) was given at a dose of 10mg/kg/day in DMSO for 3 weeks. At the end of 3 week's mice were sacrificed and tissues were collected.
For tumor initiation studies, OGT knockout (OGTi-S2VP10) cells were injected at a limiting dilution from 500,000 cells per mice to 500 cells in the right flank of female athymic nude mice. The mice were monitored daily and the appearance of tumor was noted. All the experiments were performed according to the IACUC protocols as approved by the University of Miami.
RNA Isolation and cDNA synthesis
RNA was isolated using the Trizol method of isolation and cDNA was made using the High Capacity cDNA Reverse Transcription Kit. 2 µgm of RNA was used per reaction. RT-qPCR was performed in the Roche Light Cycle 480.Primers (SOX2 PPH02471A, OCT4 PPH66786A, NANOG PPH17032E-200, OGT PPH19166A, OGA PPH01061A) were purchased from Qiagen, Valencia, CA, USA
Western Blotting
Cell lysates were prepared using RIPA lysis buffer with protease and phosphatase inhibitors.
4-20% SDS page gel were used for running the proteins.5% BSA in TBST was used as a blocking agent. SOX2 antibody (SAB2701974) was purchased from SIGMA-ALDRICH and was used at a dilution of 1:1000. Secondary anti rabbit was used at a dilution of 1:5000.
Sox2 Dual Luciferase Reporter Assay
S2VP10 and L3.6pL cells were plated at a density of 0.8X10 6 cells per well in a 24 well plate.
Cells were transfected with the SOX2 reporter plasmid the next day using Attractene as a transfection reagent. The day after the transfection with the reporter plasmid the cells were treated with OSMI and/ or MG132 at a dose of 50µM and 1µM respectively for another 24 hours respectively. 24 hours after treatment the cells were lysed and the luminescence was analyzed using a spectrophotometer.
Sox2 ELISA
For estimating the amount of SOX2 protein in our cell lysates, we performed a Sandwich ELISA using the human SOX2 ELISA kit from My Biosource, San Diego, CA, USA (MBS2513016). Cells were plated in a 10 cm dish and allowed to attach and grow for 24 hours. After 24 hours of plating cells were treated with OSMI and MG1332 alone or in combination at a dose of 50 µM and 1µM for 24 hours respectively. After 24 hours of treatment cells were lysed using RIPA lysis buffer and the protein was estimated using BCA protein estimation method. Equal amount of protein was loaded for the assay and the assay was performed according to the manufacturer's protocol.
Ethics Statement
All procedures were performed according to protocols approved by the University of Miami
Institutional Animal Care and Use Committee (IACUC).
Statistical Analysis
Values are expressed as the mean +/-SEM. All in vitro experiments were performed at least three times. The significance between any two samples was analyzed by t-test, values of p<0.05 were considered statistically significant.
RESULTS
OGT expression correlates with the aggressiveness of the disease.
OGT expression and O-GlcNAc modifications are elevated in pancreatic cancer (17) . Previously 
Down-regulation of OGT leads to a decrease in self-renewal in pancreatic cancer
Since OGT inhibition resulted in a delay in tumor initiation, we next studied the effect of this inhibition on self-renewal genes namely, SOX2, OCT4 and NANOG. Our results showed that OGT silencing (using siRNA) did not change the expression of core self-renewal transcription factors SOX2 or OCT 4 in S2VP10 cells while modestly changing its expression in L3.6pL cells (Supplementary Figure 2C, D) . However, a methyl-cellulose based colony forming unit assay on S2-VP10 and L3.6pL cells showed that treatment with OSMI (a small molecule inhibitor of OGT) decreased the colonies in S2VP10 and L3.6pL cells (Figure 3 A,B) compared to untreated cells.
Since small molecule inhibitors are notorious for their off-target effects, we next performed this assay using the OGTi-S2VP10 cells. The colony forming ability of these cells was also significantly decreased ( Figure 3B ). Since colony-forming ability is a measure of the cells selfrenewal potential, we next performed a luciferase based transcriptional activity assay on the transcription factors regulating self-renewal. Pancreatic cancer cells S2VP10, were treated with small molecule inhibitor OSMI and used for this luciferase based stem cell reporter array. Our results showed that among the 10 transcription factors involved in self-renewal SOX2 activity was the most significantly down-regulated (Supplementary Figure 3) . We validated this using a Luciferase based transcriptional activity assay for SOX2, OCT4 and Nanog using OSMI ( Figure   3C ) and siOGT on S2VP10 cells ( Figure 3D ). SOX2 transcriptional activity assay was also performed on L3.6PL cells using siOGT ( Figure 3D ) and on our OGTi-S2VP10 cells ( Figure 3E ).
Our results showed that SOX2 activity was affected significantly in cells in which OGT was inhibited either by OSMI or by siRNA compared to the control. Our results thus indicated that OGT is required for SOX2 transcriptional activity.
Transcriptional regulation of self-renewal in pancreatic cancer is dependent on O-GlcNAc modification of Sox2
Since our results indicated that OGT inhibition might affect self-renewal properties of pancreatic cancer cells via inhibition of SOX2 activity, we next studied the glycosylation of SOX2. SOX2 is modified by OGT in embryonic stem cells. This modification of SOX2 is known to play a role in its protein-protein interaction in those cells (12) . To determine if SOX2 is modified by O-GlcNAc in pancreatic cancer cells, we performed an immunoprecipitation with O-GlcNAc antibody and probed it with anti-SOX2 antibody. SOX2 was seen to be glycosylated by O-GlcNAc in this experiment ( Figure 4A ). To further confirm this, we performed a Proximal Ligation Assay (PLA) on S2-VP10 cells. Our results showed that SOX2 is indeed modified by O-GlcNAc and that inhibition of OGT by OSMI or siRNA caused a decrease in its glycosylation ( Figure 4B ). As seen with OSMI, immunofluorescence with SOX2 and O-GlcNAc in the stable KO of OGT in OGTi-S2VP10 also showed decreased glycosylation on SOX2 protein ( Figure 4C ).
To study if the modification of Sox2 is disrupted by mutating the site we next performed a site directed mutagenesis of Ser 246 to Ala in Sox2 overexpressing plasmids obtained from Addgene.
The plasmid was then transiently transfected to S2-VP10 cells for 24 hours. We observed that S246A mutation in Sox2 gene resulted in loss of O-GlcNAc modification of SOX2 as observed via immunoprecipitation ( Figure 4D ), confirming that Ser246 in SOX2 indeed gets modified by O GlcNAcylation .
O-GlcNAc modification of SOX2 is required for its stability in pancreatic cancer cells
O-GlcNAc modification of a protein can affect its activity in a number of ways. In embryonic cells, modification of SOX2 facilitates its interaction with PARP and promotes differentiation (12) . Our results (in Figure 3) showed that upon inhibition of OGT, SOX2 transcriptional activity was Figure 2C ) indicated that SOX2 mRNA remained unaltered, we concluded that inhibition of OGT was affecting the stability of SOX2 protein. It is well known that SOX2 acts as a molecular rheostat for a cancer cell and its expression needs to be tightly regulated. Thus, the degradation machinery for SOX2 needs to be fairly robust in a cell (18) . To further validate this result, we treated S2VP10 and L3.6pL cells with OSMI alone and OSMI with MG-132, a proteasome inhibitor. We observed a significant rescue in the protein levels of SOX2 when the cells were treated with the proteasome inhibitor ( Figure 5E ) thus demonstrating that O-GlcNAcylation of SOX2 is important for its stability.
Further, treatment with MG132 in the presence of OSMI also showed a rescue in the transcriptional activity of SOX2 ( Figure 5F ). Further, our studies showed that mutation of the OGlcNAc modification site (S246A) resulted in a profound decrease in the SOX2 protein levels indicating that loss of O-GlcNAc modification of Sox2 led to decreased protein ( Figure 5 G) and reduced Sox2 DNA binding activity ( Figure 5H ). We also observed that upon inhibition of OGT (by treatment with OSMI), there was an inhibition of nuclear translocation which was reverted upon treating with O-GlcNAcase inhibitor Thiamet G ( Figure 5I ). Additionally, quantitation of nuclear and cytosolic Sox2 in OGTi cells showed the same results ( Figure 5J ).
Inhibition of OGT in vivo decreases tumor burden
To evaluate the efficacy of OGT downregulation in vivo, we implanted S2VP10 cells subcutaneously in athymic nude mice. OSMI was administered at a dose of 10mg/kg/day for 30 days. Consistent with our in vitro data treatment with OSMI caused a delay in tumor progression ( Figure 6A ). Further, a significant decrease in tumor volume and weight was observed upon inhibition of OGT (Figure 6 B, C) . The tumors showed less O-GlcNAc ( Figure 6D ) and decreased cellularity in the H&E staining ( Figure 6E ). Further, as expected, there was less O-GlcNAc modification on SOX2 ( Figure 6F ). Upon analysis, the tumors showed a decrease in the OCT4
and NANOG expression when treated with OSMI (Supplementary Figure 4) .
Discussion
O-GlcNAc transferase or OGT is an enzyme that transfers a single N-Acetyl glucosamine to serine or threonine residues of many proteins. This modification can "flag" the protein for phosphorylation (19) , determine its interaction with other proteins or regulate its nuclear translocation (11, 20) . The The role of O-GlcNAc modifications in regulating stemness and self-renewal is gaining importance in cancer research (24, 25) . A recent study in embryonic stem cells has shown that Sox2, a key transcription factor for self-renewal is modified by O-GlcNAc, which in turn facilitates its interaction with PARP to regulate differentiation (12) . However, there are very few studies on whether this modification is responsible for initiation and regulation of self-renewal in cancer. Our current study
shows that inhibition of OGT by a CRISPR results in a delay in tumor formation in animals ( Figure   1 ). Tumor initiation is regulated by SOX2, OCT4 and NANOG transcription factors. These transcription factors act in a concerted manner to regulate genes that control "stemness" and differentiation and thus are responsible for recurrence of tumor. Our study shows that in pancreatic cancer, where there is a high incidence of tumor recurrence, SOX2 was getting modified by O-GlcNAc (Figure 4 ).
O-GlcNAcylation of SOX2 regulates its transcriptional activity. When OGT is inhibited either by siRNA, or the small molecule inhibitor OSMI, there is a distinct decrease in colony formation units ( Figure 3) . Further, tumors treated with OSMI in vivo showed a clear decrease in the expression of SOX2 ( Figure 6 ). Our results also showed that O-GlcNAc modification was decreasing SOX2
activity by affecting its stability and preventing its nuclear localization ( Figure 5 ). This was an interesting observation as it had been reported earlier that in embryonic stem cells, the acetylation Sox2 regulates its nuclear translocation (26, 27) . However, our studies clearly indicated that upon However, studying that is beyond the scope of the current manuscript.
The stability of SOX2 has been implicated to play a role in its function. Sumoylation of SOX2 at Lysine 247 is instrumental in inhibition of DNA binding by SOX2 (28) . Our results showed that OGlcNAc modification of SOX2 also regulates its stability ( Figure 5 ). In a number of other cancers, O-GlcNAc modification is known to regulate protein stability. In prostate cancer, O-GlcNAc modification of Bm1-1 modulates its stability and promotes oncogenic function (29, 30) . However, its role in stability of SOX2 protein in pancreatic cancer cells has not been studied before. Our study thus show for the first time that O-GlcNAc modification in pancreatic cancer may be instrumental in regulating its self-renewal properties by maintaining the stability of Sox2 and regulating its nuclear translocation.
Conclusion
Self-renewal in a tumor is considered to be one of the hallmarks of the cancer stem cells or tumor initiating cells that are responsible for tumor recurrence, chemoresistance and metastasis.
Understanding the molecular switch that can potentially turn-on the self-renewal pathway (by activating Sox2), is thus a significant area of research. In this context, our study highlights that the O-GlcNAc transferase dependent SOX2 glycosylation has a profound effect on the transcriptional activity of SOX2 as this modification regulates its nuclear translocation as well as protein stability. Understanding this mechanism of "turning-on" Sox2 by its glycosylation is thus expected to pave the way for development of novel therapy that can not only decrease tumor progression but also eradicate the "roots" of cancer or the "cancer stem cells". 
